Episode #151
Should You Buy Compass Pathways? The Magic Mushroom Stock No Analyst Will Touch $CMPS $RKLB $SHOP $PNG (E151)
Krzysztof pitches Compass Pathways: both phase 3 trials of its pharmaceutical psilocybin are already positive, approval looks likely in early 2027, and the company holds 400-plus million in cash against about 40 million a quarter of burn, which by his math is ten quarters of runway. Stanford's Kevin Mak took a position, and Krzysztof walks through Mak's seven structural reasons the stock hasn't rerated. Luke explains gilt laddering as the cash sleeve of a portfolio, which turns into an argument about whether the US can grow its way out of $40 trillion of debt with the 30-year over 5%, and he names HSBC for fumbling his CyberArk payout nearly a year after Palo Alto closed the deal. Voting is open on the September community portfolio: Kraken Robotics, Rocket Lab and Shopify. Should you buy $CMPS? The drug works, both phase 3 trials are positive, and the one grey area is whether insurers pay for a dose that needs six-plus hours of clinician supervision Kevin Mak's seven reasons: a UK ADR no US index owns, thin institutions, career risk for any analyst who says "buy the magic mushroom stock", no valuation framework, M&A unpriced. A $2 billion company sitting at $15 resistance off a low of $2; Mak's number if you run it is about $45 a share ️ September community portfolio: Kraken Robotics, $RKLB and $SHOP, voting is open at wallstreetwildlife.com Luke's Rocket Lab average buy was $3-something; it got as high as $130 and is a $60-something stock now ️ Paul thought $SHOP was overvalued until he opened his own storefront on it; Luke says Shopify got him across the line into early retirement Beginner's mind: look at a stock you think you already know with fresh eyes Gilts in a minute: short-dated UK government bonds, refreshed every six months, as the cash you never leave idle The 30-year over 5% on $40 trillion of debt: growth has to beat the interest bill, which is why Krzysztof holds Bitcoin (and the crypto that is not a crypto that shall not be mentioned) HSBC vs Trading 212 on the CyberArk acquisition: one converted in a day, one buried itself in bureaucracy and broken processes. Why you should have more than one broker once the numbers get big Luke is officially addicted to vibe coding SOURCES: Luke's Gilt webinar: https://youtu.be/HVVj0u1O6ms Jared Isaacman (NASA): https://youtu.be/VTF6p0U98ek?si=DgSH8GOAA_MuM0jb SEGMENTS: 00:00 Cold open 00:56 Jury Duty, the Amazon show: "a bit mid" or the kindest thing on TV? 06:03 Real jury duty, Bezos and Saylor on one panel, and AI judges 08:02 Luke is officially addicted to vibe coding 12:07 Livestream Monday, Patreon welcomes 14:21 A dark thought about capitalism: why are you investing, and what is enough? 19:13 What the community portfolio is, and why you should get involved 20:46 September pitches: Kraken Robotics $PNG, $RKLB and $SHOP, and beginner's mind 27:02 Fiscal.ai: fiscal.ai/wildlife, first week of Pro free, 15% off 28:03 Krzysztof already owns $RKLB, and the option that soured him 28:52 Isaacman at All-In: a moon base as the staging post to Mars 31:36 Paul's Shopify message: a merchant's beginner's mind 33:28 Should you buy $CMPS? The drug works, the cash runs ten quarters 40:31 Kevin Mak's seven structural reasons, the chart, and $45 44:25 Biotech corner: "I am a disco", Nektar, Relay, TransMedics 48:01 Cash doesn't have to sit idle: gilts and the gilt ladder 52:13 The 30-year over 5% on $40 trillion of debt: growth, Bitcoin, $ASST 57:59 Chainlink: the cryptocurrency that isn't a cryptocurrency 59:09 CyberArk deal: HSBC vs Trading 212, and why your broker matters 01:03:46 Wrap Fiscal.AI is the Complete Stock Research Platform for fundamental investors. Get 15% off any premium plan with: fiscal.ai/wildlife Disclosure: Wall Street Wildlife hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation
